CN104168921B - 用于为抗egfr药物治疗鉴定非小细胞肺癌患者的组织学标志物 - Google Patents

用于为抗egfr药物治疗鉴定非小细胞肺癌患者的组织学标志物 Download PDF

Info

Publication number
CN104168921B
CN104168921B CN201380015223.9A CN201380015223A CN104168921B CN 104168921 B CN104168921 B CN 104168921B CN 201380015223 A CN201380015223 A CN 201380015223A CN 104168921 B CN104168921 B CN 104168921B
Authority
CN
China
Prior art keywords
egfr
nsclc
cetuximab
scc
lung cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201380015223.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN104168921A (zh
Inventor
李其翔
杨蒙蒙
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhejiang Xinwei Biotechnology Co ltd
Crown Bioscience Inc Taicang
Original Assignee
Zhejiang Xinwei Biotechnology Co ltd
Crown Bioscience Inc Taicang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhejiang Xinwei Biotechnology Co ltd, Crown Bioscience Inc Taicang filed Critical Zhejiang Xinwei Biotechnology Co ltd
Priority to CN201380015223.9A priority Critical patent/CN104168921B/zh
Publication of CN104168921A publication Critical patent/CN104168921A/zh
Application granted granted Critical
Publication of CN104168921B publication Critical patent/CN104168921B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5752—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201380015223.9A 2012-07-31 2013-07-31 用于为抗egfr药物治疗鉴定非小细胞肺癌患者的组织学标志物 Expired - Fee Related CN104168921B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201380015223.9A CN104168921B (zh) 2012-07-31 2013-07-31 用于为抗egfr药物治疗鉴定非小细胞肺癌患者的组织学标志物

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CNPCT/CN2012/079399 2012-07-31
CN2012079399 2012-07-31
CN201380015223.9A CN104168921B (zh) 2012-07-31 2013-07-31 用于为抗egfr药物治疗鉴定非小细胞肺癌患者的组织学标志物
PCT/US2013/053091 WO2014028221A1 (en) 2012-07-31 2013-07-31 Histological markers for identifying non-small cell lung carcinoma patients for treatment with an anti-egfr drug

Publications (2)

Publication Number Publication Date
CN104168921A CN104168921A (zh) 2014-11-26
CN104168921B true CN104168921B (zh) 2018-06-08

Family

ID=50101405

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380015223.9A Expired - Fee Related CN104168921B (zh) 2012-07-31 2013-07-31 用于为抗egfr药物治疗鉴定非小细胞肺癌患者的组织学标志物

Country Status (6)

Country Link
US (1) US9921222B2 (enExample)
EP (1) EP2879712B1 (enExample)
JP (1) JP6324381B2 (enExample)
CN (1) CN104168921B (enExample)
ES (1) ES2668861T3 (enExample)
WO (1) WO2014028221A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017527627A (ja) * 2014-09-16 2017-09-21 アッヴィ・インコーポレイテッド 喫煙者における非小細胞肺癌の治療のための、カルボプラチンおよびパクリタキセルと併用したベリパリブ
CN110520543A (zh) 2017-03-29 2019-11-29 中美冠科生物技术（太仓）有限公司 确定胃癌对西妥昔单抗敏感性的系统和方法
CN112813164A (zh) * 2021-01-18 2021-05-18 四川省肿瘤医院 Ereg促进nsclc细胞对egfr-tki产生耐药性原因的验证方法
CN115810399A (zh) * 2022-11-14 2023-03-17 南京工业大学 一种基于转录模式的肺腺癌组织学亚型分类方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
US5942602A (en) 1997-02-13 1999-08-24 Schering Aktiengessellschaft Growth factor receptor antibodies
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
EP2110138A1 (en) 1999-08-27 2009-10-21 Genentech, Inc. Dosages for treatment of anti-erbB2 antibodies
EP1622941A2 (en) 2003-03-20 2006-02-08 ImClone Systems Incorporated Method of producing an antibody to epidermal growth factor receptor
ES2387809T3 (es) 2004-03-19 2012-10-02 Imclone Llc Anticuerpo frente al receptor del factor de crecimiento epidérmico humano
SI1913157T2 (sl) 2005-06-28 2017-02-28 Genentech, Inc. EGFR in KRAS mutacije za napoved bolnikovega odziva na zdravljenje z EGFR inhibitorjem
JP2009515878A (ja) 2005-11-12 2009-04-16 イーライ リリー アンド カンパニー 抗ｅｇｆｒ抗体
AU2007353412A1 (en) 2006-11-21 2008-11-20 Fox Chase Cancer Center Anti-EGFR family antibodies, bispecific anti-EGFR family antibodies and methods of use thereof
US7977336B2 (en) 2006-12-28 2011-07-12 Banyu Pharmaceutical Co. Ltd Aminopyrimidine derivatives as PLK1 inhibitors
KR100968591B1 (ko) 2007-06-14 2010-07-08 한국과학기술연구원 약물전달용 폴리포스파젠계 하이드로젤, 그의 제조방법 및그의 용도
US20100009390A1 (en) 2008-05-09 2010-01-14 The Regents Of The University Of California Mutant antibodies with high affinity for egfr
KR20110047255A (ko) 2008-09-26 2011-05-06 로슈 글리카트 아게 이중특이적 항-ｅｇｆｒ／항-ｉｇｆ-１ｒ 항체
WO2010080463A1 (en) 2008-12-18 2010-07-15 Imclone Llc Antibody humanization
KR101108642B1 (ko) 2009-09-29 2012-02-09 주식회사 녹십자 표피 성장 인자 수용체에 특이적으로 결합하는 항체
US8658175B2 (en) 2009-10-28 2014-02-25 Abbvie Biotherapeutics Inc. Anti-EGFR antibodies and their uses
US20110118298A1 (en) * 2009-11-13 2011-05-19 Infinity Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer
US20110158987A1 (en) 2009-12-29 2011-06-30 F. Hoffmann-Laroche Ag Novel antibody formulation
JP2011144124A (ja) 2010-01-13 2011-07-28 Fujirebio Inc 活性型ｅｇｆｒ特異抗体
WO2011140151A1 (en) 2010-05-04 2011-11-10 Dyax Corp. Antibodies against epidermal growth factor receptor (egfr)
WO2011140254A1 (en) 2010-05-04 2011-11-10 Adimab, Llc Antibodies against epidermal growth factor receptor (egfr) and uses thereof
US9029513B2 (en) 2010-06-04 2015-05-12 Toagosei Co. Ltd. Anti-EGFR antibody and use thereof
WO2011156617A2 (en) 2010-06-09 2011-12-15 Aveo Pharmaceuticals, Inc. Anti-egfr antibodies
BR112013003257A2 (pt) 2010-08-10 2016-06-14 Glycotope Gmbh anticorpos egfr humanizados.
US9155802B2 (en) 2010-11-01 2015-10-13 Symphogen A/S Pan-HER antibody composition
US8691231B2 (en) 2011-06-03 2014-04-08 Merrimack Pharmaceuticals, Inc. Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomized phase III trial;pirker r et al;《the lancet》;20090508;第373卷(第9674期);1525-1531 *
phase II study of cetuximab, docetaxel, and gemcitabine in patients with previously untreated advanced non-small-cell lung cancer;spigel dr et al;《clinical lung cancer》;20100531;第11卷(第3期);198-203 *
prognostic factors in patients with advanced non-small-cell lung cancer: data from the phase III FLEX study;pirker r et al;《lung cancer》;20120411;第77卷(第2期);376-382 *

Also Published As

Publication number Publication date
WO2014028221A1 (en) 2014-02-20
ES2668861T3 (es) 2018-05-22
EP2879712B1 (en) 2018-04-25
EP2879712A1 (en) 2015-06-10
CN104168921A (zh) 2014-11-26
US9921222B2 (en) 2018-03-20
JP6324381B2 (ja) 2018-05-16
JP2015527341A (ja) 2015-09-17
US20150168411A1 (en) 2015-06-18
EP2879712A4 (en) 2016-03-16

Similar Documents

Publication Publication Date Title
Lv et al. Value of 18F–FDG PET/CT for predicting EGFR mutations and positive ALK expression in patients with non-small cell lung cancer: a retrospective analysis of 849 Chinese patients
Yoon et al. Phase II study of neoadjuvant bevacizumab and radiotherapy for resectable soft tissue sarcomas
Moehler et al. An open-label, multicentre biomarker-oriented AIO phase II trial of sunitinib for patients with chemo-refractory advanced gastric cancer
Okines et al. Biomarker analysis in oesophagogastric cancer: Results from the REAL3 and TransMAGIC trials
JP6695003B2 (ja) 癌のための併用療法
US10442862B2 (en) Use of EGFR biomarkers for the treatment of gastric cancer with anti-EGFR agents
KR20130055647A (ko) 항암요법에 반응할 가능성이 증가된 환자를 확인하는 방법
JP2014518610A (ja) 前立腺癌細胞系、遺伝子シグネチャー及びその使用
CN105407913A (zh) 用于鉴定可用抗egfr药物治疗的食管癌患者的生物标志物
CN107750165A (zh) 借助塞里班土单抗的组合治疗
Choi et al. AXL and MET receptor tyrosine kinases are essential for lung cancer metastasis Corrigendum in/10.3892/or. 2017.5482
EP2879712B1 (en) Histological markers for identifying non-small cell lung carcinoma patients for treatment with an anti-egfr drug
KR20110140126A (ko) 항-ｅｇｆｒ 작용제(들) 및 ｉｇｆ-1ｒ 특이적 억제제를 사용하는 조합 요법
Mimae et al. Protein expression and gene copy number changes of receptor tyrosine kinase in thymomas and thymic carcinomas
JP2017535548A (ja) Ｖｅｇｆアンタゴニストの応答の予測
WO2020128637A1 (en) Use of il-1 binding antibodies in the treatment of a msi-h cancer
Carter et al. Post-chemotherapy and targeted therapy imaging of the chest in lung cancer
Steendam et al. Randomized phase III study of docetaxel versus docetaxel plus intercalated erlotinib in patients with relapsed non-squamous non-small cell lung carcinoma
US20150218647A1 (en) Biomarkers for identifying esophageal cancer patients for treatment with an anti-egfr drug
US12560611B2 (en) Ratio between PLGF and sFLt1 is predictive for neural invasion in patients suffering from pancreatic cancer
Felsberg et al. Prognostic role of epidermal growth factor receptor variant III (EGFRvIII) positivity in EGFR-amplified primary and recurrent glioblastomas
WO2025085404A1 (en) Diagnostic and therapeutic methods for treating lung cancer
Ju et al. Neoadjuvant chemo-free combination of camrelizumab and apatinib for locally advanced resectable oral squamous cell carcinoma–A pilot study
WO2023096651A1 (en) Methods for treating bile duct cancers with tivozanib
WO2020161614A1 (en) Methods for treating triple negative breast cancer using a human erbb-2 mutant protein

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: CROWN (TAICANG) BIOSCIENCE INC.

Free format text: FORMER OWNER: CROWN BIOSCIENCE INC.

Effective date: 20150723

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20150723

Address after: 215400 science and Technology Pioneer Park, No. 6 West Beijing Road, Taicang Economic Development Zone, Jiangsu, China

Applicant after: Sino American crown (Taicang) Biotechnology Co.,Ltd.

Address before: California, USA

Applicant before: CROWN BIOSCIENCE Inc. (TAICANG)

CB02 Change of applicant information

Address after: 215400 science and Technology Pioneer Park, No. 6 West Beijing Road, Taicang Economic Development Zone, Jiangsu, China

Applicant after: CROWN BIOSCIENCE Inc. (TAICANG)

Address before: 215400 science and Technology Pioneer Park, No. 6 West Beijing Road, Taicang Economic Development Zone, Jiangsu, China

Applicant before: Sino American crown (Taicang) Biotechnology Co.,Ltd.

CB02 Change of applicant information
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20170930

Address after: 215400 Jiangsu Taicang Economic Development Zone Beijing West Road 6 science and Technology Pioneer Park

Applicant after: CROWN BIOSCIENCE Inc. (TAICANG)

Applicant after: Zhejiang Xinwei Biotechnology Co.,Ltd.

Address before: 215400 science and Technology Pioneer Park, No. 6 West Beijing Road, Taicang Economic Development Zone, Jiangsu, China

Applicant before: CROWN BIOSCIENCE Inc. (TAICANG)

GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20180608